Excelimmune, Inc., a Woburn, MA-based biopharmaceutical company, has raised $12m from an undisclosed private investor.
The company intends to use the capital to develop its infectious disease programs, including Staphguard, a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA), and to expand its discovery programs to new disease targets beyond infectious diseases through its antibody screening technology.
Founded in 2006 and led by CEO Quinton Zondervan, Excelimmune specializes in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans.
Initially focused on infections caused by Staphylococcus aureus, the company’s technology is believed to be also applicable in the treatment of other pathogenic bacteria and viruses, disease causing proteins, and cancer.
FinSMEs
20/12/2011